Detalhe da pesquisa
1.
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 168(1): 127-134, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164421
2.
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Am J Hematol
; 93(5): 607-614, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352732
3.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Lancet Oncol
; 17(2): 212-223, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26727163
4.
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 27(13): 3630-3640, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820783
5.
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
ESMO Open
; 5(4)2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661186
6.
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Clin Cancer Res
; 20(7): 1935-45, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24470511